The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa
Open Access
- 31 May 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (5), e36966
- https://doi.org/10.1371/journal.pone.0036966
Abstract
We estimated the incremental cost and impact on diagnosis and treatment uptake of national rollout of Xpert MTB/RIF technology (Xpert) for the diagnosis of pulmonary TB above the cost of current guidelines for the years 2011 to 2016 in South Africa. We parameterised a population-level decision model with data from national-level TB databases (n = 199,511) and implementation studies. The model follows cohorts of TB suspects from diagnosis to treatment under current diagnostic guidelines or an algorithm that includes Xpert. Assumptions include the number of TB suspects, symptom prevalence of 5.5%, annual suspect growth rate of 10%, and 2010 public-sector salaries and drug and service delivery costs. Xpert test costs are based on data from an in-country pilot evaluation and assumptions about when global volumes allowing cartridge discounts will be reached. At full scale, Xpert will increase the number of TB cases diagnosed per year by 30%–37% and the number of MDR-TB cases diagnosed by 69%–71%. It will diagnose 81% of patients after the first visit, compared to 46% currently. The cost of TB diagnosis per suspect will increase by 55% to USD 60–61 and the cost of diagnosis and treatment per TB case treated by 8% to USD 797–873. The incremental capital cost of the Xpert scale-up will be USD 22 million and the incremental recurrent cost USD 287–316 million over six years. Xpert will increase both the number of TB cases diagnosed and treated and the cost of TB diagnosis. These results do not include savings due to reduced transmission of TB as a result of earlier diagnosis and treatment initiation.Keywords
This publication has 12 references indexed in Scilit:
- Is Scale-Up Worth It? Challenges in Economic Analysis of Diagnostic Tests for TuberculosisPLoS Medicine, 2011
- Comparison of Xpert MTB/RIF with Other Nucleic Acid Technologies for Diagnosing Pulmonary Tuberculosis in a High HIV Prevalence Setting: A Prospective StudyPLoS Medicine, 2011
- The role of health economics research in implementation research for health systems strengthening [State of the art series. Operational research. Number 6 in the series]The International Journal of Tuberculosis and Lung Disease, 2011
- Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation studyThe Lancet, 2011
- Laboratory Diagnosis of Tuberculosis in Resource-Poor Countries: Challenges and OpportunitiesClinical Microbiology Reviews, 2011
- Rapid Molecular Detection of Tuberculosis and Rifampin ResistanceNew England Journal of Medicine, 2010
- Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting.2010
- TB diagnostic tests: how do we figure out their costs?Expert Review of Anti-infective Therapy, 2009
- Faculty Opinions recommendation of Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis.Published by H1 Connect ,2008
- Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changesThe Lancet, 2007